Illinois Rep. John Shimkus, a well-known pro-medtech industry bill sponsor, announced on 30 August his plans for a January 2020 retirement. He joins at least 15 Republican House members who recently said they are also ending their Capitol Hill careers, leaving six vacancies on the US House Energy and Commerce and Ways and Means panels prior to the 2020 elections.
A group of Republicans sitting on key US House panels that passed bills favorable to medtech firms in 2016 just announced their planned retirements prior to the 2020 elections, including Rep. John Shimkus of Illinois, who sponsored several pro-industry bills that are now part of the 21st Century Cures Act.
Among the 15 House GOP members planning to leave the chamber next year are six who sit on the two...
Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.
A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.
